United States

Tocagen receives FDA Breakthrough designation for glioma

Friday, February 24, 2017

Tocagen, a clinical-stage, cancer-selective gene therapy company, has announced the FDA granted Toca 511 & Toca FC Breakthrough Therapy designation for the treatment of patients with recurrent high grade glioma (HGG). Toca 511 & Toca FC is currently under evaluation in an international, randomized phase II/III clinical trial, which is designed to serve as a potential registrational study. The trial involves patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection. Enrollment in the phase II portion of the trial has completed and top-line results are anticipated in the first half of 2018.

[Read More]

NIH launches MarkVCID dementia biomarkers consortium

Friday, February 24, 2017

To better predict, study, and diagnose small vessel disease in the brain and its role in vascular contributions to cognitive impairment and dementia (VCID), the NIH has launched MarkVCID, a consortium designed to accelerate the development of new and existing biomarkers for small vessel VCID.

[Read More]

Survey: Patients access to medical records critical to high-quality healthcare

Wednesday, February 22, 2017

In the era of digital health, patients have very high expectations for medical information sharing, but they may not be aware of the healthcare industry’s current limitations. That’s according to a new digital health survey released today by Transcend Insights, a population health management company. The survey found that a vast majority of patients (97%) believe it is important for any health institution, regardless of type or location, to have access to their full medical history in order to receive high-quality care.

[Read More]

Report: Device tax cost medtech industry 29k jobs

Monday, February 13, 2017

The U.S. medical technology industry saw its jobs ranks fall by nearly 29,000 while the medical device excise tax was in effect, according to the latest figures from the U.S. Department of Commerce. Specifically, from 2012 to 2015, the number of U.S. medtech jobs declined from 401,472 to 372,638—a loss of 28,834 jobs or a 7.2% decrease for the time period.

[Read More]

FDA approves EMFLAZA for Duchenne muscular dystrophy

Monday, February 13, 2017

Marathon Pharmaceuticals, a U.S. research-based biopharmaceutical company focused solely on the development of new treatments for rare diseases, has announced that the FDA granted approval of EMFLAZA (deflazacort) for the treatment of Duchenne muscular dystrophy in patients 5 years and older. Duchenne, a severe form of muscular dystrophy, is a rare disease and fatal genetic disorder that affects about 15,000 people in the U.S.

[Read More]